US4518611A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2-Furylbutyrolactone modulation of the immune system in mammals
Assignee: NATIONAL FOUNDATION FOR CANCER RESEARCH Inc A MA CORP
•
Filing: 1983-09-29
•
Granted: 1985-05-21
•
Expires: 2003-09-29
Abstract
Abstract Compositions containing compounds which exhibit immunomodulatory properties can be used as immunostimulants or immunosuppressants in humans and animals.
Inventors
- 👤 Robert W. Veltri
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:57
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/01; C07D; C07D307/00; C07D307/02; C07D307/34; C07D307/56; C07D307/60
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
176 words
A method for modulating in stimulation or suppression mode the lymphocyte system of mammals comprising administering a composition comprising a modulatorily effective amount of a compound of the formula: ##STR16## wherein: R 2 is selected from the group consisting of hydrogen and lower alkyl; R 5 and R 6 are selected from the group consisting of hydrogen and lower alkyl and may be the same or different; R 8 is selected from the group consisting of hydrogen and lower alkyl; R 7 is hydrogen, lower alkyl or ##STR17## R 9 is CH 2 OH R 10 is hydrogen; when R 7 contains a hydroxyl group in the α or β position, R 7 may form the hemiketal ring closure at carbon 3 of the butyrolactone with protonation of the carbonyl group on the same carbon atom and X is selected from the group consisting of O, S and NH the low dosage corresponding to the stimulatory mode of modulation and the high dosages corresponding to the suppression mode of modulation and a pharmaceutically acceptable carrier therefor.
Claim 2
Independent Claim
176 words
A method for modulating in stimulation or suppression mode the lymphocyte system of mammals comprising administering a composition comprising a modulatorily effective amount of a compound of the formula: ##STR16## wherein: R 2 is selected from the group consisting of hydrogen and lower alkyl; R 5 and R 6 are selected from the group consisting of hydrogen and lower alkyl and may be the same or different; R 8 is selected from the group consisting of hydrogen and lower alkyl; R 7 is hydrogen, lower alkyl or ##STR17## R 9 is CH 2 OH R 10 is hydrogen; when R 7 contains a hydroxyl group in the α or β position, R 7 may form the hemiketal ring closure at carbon 3 of the butyrolactone with protonation of the carbonyl group on the same carbon atom and X is selected from the group consisting of O, S and NH the low dosage corresponding to the stimulatory mode of modulation and the high dosages corresponding to the suppression mode of modulation and a pharmaceutically acceptable carrier therefor.
Claim 3
Dependent Claim
52 words
The method of claim 1, wherein: R 2 is --CH 3 ; R 5 and R 6 are each hydrogen; X is O; R 9 is --CH 2 OH; and R 7 forms the hemiketal ring closure at carbon 3 of the butyrolactone with protonation of the carbonyl group at carbon 3.
Claim 4
Dependent Claim
15 words
The method of claim 1, wherein said pharmaceutical carrier comprises a buffered, isotonic saline solution.
Claim 5
Dependent Claim
34 words
The method of claim 1, wherein the lymphocyte system in mammals is suppressed, comprising administering a composition comprising a suppressively effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 6
Dependent Claim
25 words
The method of claim 4, wherein said composition is administered in a therapeutic dosage comprising about 300 to 1,000 mg per kg of body weight.
Claim 7
Dependent Claim
25 words
The method of claim 4, wherein said composition is administered in a preferred dosage comprising about 400 to 800 mg per kg of body weight.
Claim 8
Dependent Claim
34 words
The method of claim 1, wherein the lymphocyte system in mammals is stimulated, comprising administering a composition comprising a stimulatory effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 9
Dependent Claim
25 words
The method of claim 7, wherein said composition is administered in the therapeutic dosage comprising about 10 to 300 mg per kg of body weight.
Claim 10
Dependent Claim
25 words
The method of claim 7, wherein said composition is administered in a preferred dosage comprising about 50 to 200 mg per kg of body weight.
Claim 11
Dependent Claim
25 words
The method of claim 1, wherein said composition is administered in a therapeutic dosage comprising about 10 to 1,000 mg per kg of body weight.
Claim 12
Dependent Claim
15 words
The method of claim 1, wherein said administration of said composition is by intraperitoneal injection.
Claim 13
Dependent Claim
13 words
The method of claim 1, wherein said administration of said composition is oral.
Claim 14
Dependent Claim
13 words
The method of claim 1, wherein said administration of said composition is subcutaneous.
Claim 15
Dependent Claim
13 words
The method of claim 1, wherein said administration of said composition is intravenous.
Claim 16
Dependent Claim
13 words
The method of claim 1, wherein said administration of said composition is intramuscular.
Claim 17
Dependent Claim
36 words
The method of claim 1 wherein the chemotoxic or phagocytoxic response of components of said lymphocyte ststem is stimulated by administering an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier therefor.
References Cited (Backward Citations)
US4287205A
Cited
US4238500A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-20 | 1988-11-19 | 1989-05-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-20 | 1992-11-19 | 1993-05-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-20 | 1996-11-19 | 1997-05-21 | $7700.00 | Window Closed / Lapsed |